Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 3Neoplasms 2Synovial Cyst 1Spondylosis 1Spondylolisthesis 1Spinal Stenosis 1Radiculopathy 1Pilonidal Sinus 1Pain, Postoperative 1Neoplasms, Second Primary 1Musculoskeletal Diseases 1Malignant Neoplasms of Male Genital Organs 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hot Flashes 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Agnosia 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Clonidine × Clear all
NCT04030572 2021-06-24

a2a Agonist

Weill Medical College of Cornell University

Phase EARLY_PHASE1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡